Member Info for tqhussain

why dont you give them a call and ask them to shed some light or maybe explain what this means

Where have you read this? Nighthawk have you heard/read anything in regards to what skiv71 was mentioned

LONDON, Sept 25 (Reuters) - A new once-daily Novartis drug for treating 'smoker's lung', or COPD, has been recommended for approval in Europe, the European Medicines Agency said on Friday. The green light is a boost for the Swiss drugmaker's ambitions in respiratory medicine, a field currently dominated by GlaxoSmithKline, AstraZeneca and Pfizer . QAB149, or indacaterol, is the first once-daily bronchodilator treatment for adult patients with chronic obstructive pulmonary disease (COPD). When approved, the drug and its inhaler device, Concept-1, will be known as Onbrez Breezhaler. 'On approval, our plans are for QAB149 to form the foundation of a new portfolio of potential products designed to improve patients' respiratory health,' said Trevor Mundel, head of development at Novartis. The European Commission generally follows the recommendations of the London-based medicines agency and delivers its final decision within three months. Novartis will initially sell QAB149 as a monotherapy. But industry analysts believe unlocking the medicine's full sales potential -- which some have put at $3-5 billion a year -- will depend on combining QAB149 with other treatments. Novartis is studying combinations with NVA237, a new drug it is developing with Vectura, and with Schering-Plough's inhaled steroid mometasone. Those combinations may not reach the market until around 2013, analysts estimate.

Cheers, Will keep an eye on this for the time being

I dont know much about this share. will this drop further? worth a punt?

still the SP falls

i.e. from hold to buy

sell:3.75 buy:4

its started to move

very big pharmaceutical companies Vectura has development collaborations with several pharmaceutical companies, including Boehringer Ingelheim, Novartis, Sandoz (the generics arm of Novartis), Baxter, GlaxoSmithKline (GSK), Mylan, UCB and Otsuka. Vectura has been included in the FTSE 250 index since 23 March 2009. For further information, please visit Vectura's website at www.vectura.com

Im in

Ive been trying to track you down, lol. Ive been told you have done a blog in the general chat section on tips on how to research a company. would you be kind enough to post a link? i had a look but couldnt find anything.

Look at the volume of buys

I think we could see £3 by mid August

I agree, but patients is needed. steady rise will be seen here. Investors will target gold mining companies with the current high gold prices it will also encourage companies to start mining more to take advantage of the high prices. so all in all high gold prices are good.

sell: 60p buy: 62p

This has got some potential

sell: 11.5 buy: 12. might see 13p this afternoon

3 x 25k volume buys

lol, ok keep us updated, thanks for the info